Cholera outbreaks in Zimbabwe
Research on the mechanisms involved in neurodegenerative diseases such as Alzheimer’s, stroke, dementia, Parkinson’s and multiple sclerosis, to name a few, has taken a step forward thanks to the work of biological sciences Ph.D. student Sonia Do Carmo, supervised by Professor ?ic Rassart of the Université du Québec ?ontreal (UQAM) Biological Sciences Department, in collaboration
Full Post: Apolipoprotein D protects against Alzheimer’s
As of 1 December 2008, the Ministry of Health in Zimbabwe has reported a total of 11 735 cholera cases with 484 deaths since August 2008, affecting all provinces in the country. The overall case fatality rate is 4% but has reached up to 20?C30% in remote areas. Out of the total number of cases, 50% have been reported from Budiriro, a high density suburb of the capital city, Harare.
Beitbridge, a town bordering South Africa, has reported 26% of all cases. In the last two days, two additional areas have been affected: Chegutu (in Mashonaland West province) and Mvuma (in Midlands province). Reports have also been received from the Ministries of Health in neighbouring countries confirming cholera cases have occurred in Musina (South Africa), Palm Tree (Botswana) and Guro district (Mozambique).
Cholera outbreaks have become more frequent in Zimbabwe since the early 1990s. However, with the exception of the large outbreaks that occurred in 1999 and 2002, the disease has been kept under control through intensified prevention and preparedness activities.
Cholera is mainly transmitted through contaminated water and food and is closely linked to inadequate environmental management. Recent interruptions to the water supplies, together with overcrowding, are aggravating factors in this epidemic. ZINWA (Zimbabwe National Water Authority) has pledged to correct the water supply and sewage system as a matter of urgency.
The Ministry of Health and WHO, together with its health sector partners (UNICEF, IOM, OXFAM-GB, Medecins du Monde, ICRC, ACF, MSF?\Spain - Holland & Luxemburg, Plan International, GOAL, Save the Children-UK and others), have established a comprehensive and coordinated cholera response operational plan to address the needs of the population in the affected areas, emphasizing a multi-sectoral response. WHO is procuring emergency stocks of supplies to meet identified gaps and is deploying a full outbreak investigation and response team, including epidemiologists, water and sanitation engineers and social mobilization specialists. In addition, an epidemiologist and three data managers from the WHO Inter-country Support Team in Harare are assisting the WHO Country Office in data monitoring, analysis and mapping.
Communities are being encouraged to protect themselves against cholera by adhering to proper food safety practices as well as to good personal hygiene. Early rehydration at home by using oral rehydration salts is paramount to diminishing mortality.
Mass chemoprophylaxis with antibiotics is strongly discouraged, as it has no effect on the spread of cholera, can have adverse effects by increasing antimicrobial resistance and provides a false sense of security.
Once an outbreak has started, WHO does not recommend the use of the current internationally available WHO prequalified oral cholera vaccine. This is due to its 2-dose regimen, the time required to reach protective efficacy and the high cost and heavy logistics associated with its use.
The use of the parenteral cholera vaccine has never been recommended by WHO due to its low protective efficacy and the occurrence of severe adverse events.
In controlling the spread of cholera, WHO does not recommend any special restrictions to travel or trade to or from affected areas. However, neighbouring countries are encouraged to strengthen their active surveillance and preparedness systems.
Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia, found a study by a team of researchers from Switzerland and the United Kingdom. In many industrialized countries, polysaccharide pneumococcal vaccines (PPVs) are currently recommended to help prevent pneumococcal disease in people aged 65 and over and for younger people with
Full Post: Pneumococcal polysaccharide vaccines do not appear to protect against pneumonia
Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome. Malaria is caused by Plasmodium falciparum, the most deadly malaria parasite transmitted by the female anopheles mosquito and is the leading killer of children under the age of five
Full Post: Vaccine against malaria could be ready in 5 years
One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa. In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm
Full Post: Fractional dose of scarce meningitis vaccine may be effective in outbreak control
The University of Maryland, Baltimore (UMB) has licensed a pediatric vaccine against Shigella bacteria to PATH, an international nonprofit group, to support clinical trials, with the goal of developing a vaccine suitable for children in resource-poor countries. Each year, an estimated 1.1 million people die from Shigella infections, a major cause of diarrhea and dysentery,
Full Post: Live oral Shigella vaccine licensed to PATH
Most of the rabies virus circulating in dogs in western and central Africa comes from a common ancestor introduced to the continent around 200 years ago, probably by European colonialists. In the current issue of Journal of General Virology a team of scientists from Africa, USA and France report that within this common ancestry there
Full Post: Hope for a rabies eradication strategy in Africa